United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - famciclovir - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - famciclovir - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - famciclovir - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rivopharm (uk) ltd - famciclovir - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - famciclovir - oral tablet - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - famciclovir - film-coated tablet - 250 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; famciclovir

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - famciclovir - oral tablet - 250mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famciclovir, quantity: 250 mg - tablet - excipient ingredients: titanium dioxide; poloxamer; macrogol 8000; hypromellose; stearic acid - famciclovir is indicated for:. - the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients.. - the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older.. - suppression of recurrent genital herpes.. - the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients.. famciclovir is indicated in immunocompromised patients for:. - treatment of uncomplicated herpes zoster;. - treatment of recurrent herpes simplex;. - suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famciclovir, quantity: 125 mg - tablet - excipient ingredients: titanium dioxide; hypromellose; macrogol 8000; stearic acid; poloxamer - famciclovir is indicated for:. - the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients.. - the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older.. - suppression of recurrent genital herpes.. - the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients.. famciclovir is indicated in immunocompromised patients for:. - treatment of uncomplicated herpes zoster;. - treatment of recurrent herpes simplex;. - suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famciclovir, quantity: 500 mg - tablet - excipient ingredients: stearic acid; macrogol 8000; hypromellose; poloxamer; titanium dioxide - famciclovir is indicated for:,= treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients.,= treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older.,= suppression of recurrent genital herpes.,= treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients.,famciclovir is also indicated in immunocompromised patients for:,= treatment of uncomplicated herpes zoster,= treatment of recurrent herpes simplex,= suppression of recurrent herpes simplex.